BioScrip Inc. (NASDAQ: BIOS) is the largest independent national provider of infusion and home care management solutions, with approximately 2,500 teammates and nearly 80 service locations across the U.S. BioScrip partners with physicians, hospital systems, pharmaceutical manufacturers and skilled nursing facilities to provide patients access to post-acute care services.
Fully integrated high-touch solutions:
On March 15th, The Company announced its fourth quarter and full year 2018 financial results; BioScrip delivered record comparable net revenue growth of almost 8% in the fourth quarter of 2018. Excluding the bad debt adjustment, the company achieved adjusted EBITDA of $52.6 million for the year, which was slightly below the low-end of the management expectations due to slower than anticipated revenue growth in the month of December. However, the company commenced 2019 on a very strong note, with gross revenue growth of approximately 9% in both January and February, and March gross revenue to date trending at similar levels.
More recently, BioScrip and Option Care jointly announced a definitive merger agreement, which will create the nation’s preeminent home infusion company and transform the industry. The combined company will have a national footprint of more than 150 locations in 46 states and revenue exceeding $2.6 billion, as well as improved financial strength and flexibility through an optimized capital structure. The market is hugely excited about the value this combination will create for all of its combined stakeholders and patients and look forward to closing the transaction.
The transaction, which is expected to be completed in the second half of 2019, is subject to the satisfaction of customary closing conditions, including regulatory approvals and approval by BioScrip shareholders.
Receive our breakout reports in real time text the word TRADERS to 25827 – Traders News Source recent picks, track record and about us – https://tradersnewssource.com/traders-news-source-new-members/
Synergies from combining two industry leaders in home infusion:
Unique & differentiating factors:
About BioScrip: BioScrip came about in 2005 through a merger between Chromined Inc. and MIM Corporation. Chromined was founded in 1985 turned public in 1992. The company focused on the distribution of infusible medications to patients with special conditions. MIM Corp also focused on enhancing the quality of patient life through pharmacy benefit and healthcare solutions.
- BIOS provide patients with post-acute home infusion therapy healthcare services.
- BIOS are leading the shift in healthcare from the hospital to the low-cost home setting preferred by patients.
- The company’ solutions improve patient quality of life and reduce overall healthcare system utilization and costs. BIOS partner with physicians, hospital systems and healthcare payers.
- A patient-centric culture guides BIOS and focus on delivering clinical excellence, unparalleled customer service, and superior outcomes.
About Option Care: Option Care Enterprises, Inc. is one of the nation’s largest and most trusted providers of home and alternate treatment site infusion services. Holding accreditations from industry quality organizations ACHC, PCAB, ASHP, and URAC,* the company draws on nearly 40 years of clinical care experience to offer patient-centered therapy management. Option Care’s signature Home Infusion Plus services include the clinical management of infusion medicines, nursing support, and care coordination. Option Care’s multidisciplinary team of more than 1,800 clinicians – including pharmacists, nurses, and dietitians – are able to provide home infusion service coverage for nearly all patients across the United States needing treatment for complex and chronic conditions.
Want more Traders News Source Research? Download our free mobile App. Search “Traders News Source” on the APP Store or Google Play.
Home Infusion Market Overview: Expanding Home Infusion Market: Attractive Market Growth + Significant Site of Care Opportunity: Global market for Home infusion is estimated at $100B. Out of which, U.S. market is growing organically by 5%-7%. From a competitive landscape perspective; the home infusion market is highly fragmented with four large national providers. Therefore, the industry has significant consolidation opportunities with 800+ individual small-scale infusion companies in the U.S. Hospital systems, physicians, and skilled nursing centers.
Fourth Quarter 2018 Highlights
- Net revenue of $183.6 million, up 2.8% compared to $178.5 million in the fourth quarter of 2017, on a comparable ASC 606 basis.
- The company recorded a lousy debt adjustment which reduced both net revenue and adjusted EBITDA by $7.5 million.
- Net revenue year over year growth of 7.8%, excluding bad debt expense of $13.3 million and $4.0 million from both current and prior year net revenue.
- Net loss from continuing operations of $15.4 million, compared to $1.7 million in the prior year.
- Adjusted EBITDA of $11.6 million, or $19.1 million before the $7.5 million bad debt adjustment, compared to $17.1 million in the prior year quarter.
- Liquidity of $14.5 million at December 31, 2018, consisting of cash and cash equivalents.
- Net revenue of $708.9 million, compared to $793.5 million in 2017, on a comparable ASC 606 basis.
- Net loss from continuing operations of $51.6 million, compared to $63.3 million in 2017.
- Adjusted EBITDA of $45.1 million, or $52.6 million before the bad debt expense adjustment of $7.5 million, compared to $45.0 million in the prior year.
Key Stock Influences
Some key influences that might govern future stock price performance include:
- Widespread acceptance of the company’s services could be a catalyst.
- The outcome of the synergies as envisaged and the upcoming guidance for the merged entity would be a major catalyst for the company
- Further improvement in the company’s operating and market risk profile could be a medium-term catalyst. The full-fledged impact of the company’s cost reduction & resource optimization initiatives is yet to be seen.
- Notwithstanding recent improvements, BioScrip’s capital structure is still leveraged, which could indicate a need for additional funding.
- BIOS’ ability to maintain its liquidity and financial flexibility to fund its incremental capital requirements. Also, any additional equity raise is exposed to significant dilution risk.
- The company’s business risk profile is impinged by competitive pressure. Although BioScrip is making an effort to improve its operating margin through financial improvement initiatives, it is still facing challenges in achieving a competitive operating margin.
On Friday, March 15th, 2019, BIOS shares closed at $2.78 on an average volume of 0.95 million exchanging hands. Market capitalization is $355.57 Million. The current RSI is 30.25
In the past 52 weeks, shares of BIOS have traded as low as $2.32 and as high as $4.14
At $2.78, shares of BIOS are trading below their 50-day moving average (MA) at $3.53 and below their 200-day MA at $3.17
The present support and resistance levels for the stock are at $1.52 and $4.40 respectively.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.
This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.
We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.
When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.
Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.